Clinical Trials - malecare.org

From the 2013 2013 Genitourinary Cancers Symposium: High-Risk Prostate Cancer Treated with Pelvic Radiotherapy and 36 Versus 18 Months of Androgen Blockade

Men who are diagnosed with high risk prostate cancer, meaning they are more likely to develop advanced prostate cancer are usually treated with Radiotherapy (RT) and long term androgen blockade (AB). Currently, we do not know what is the optimal duration of AB. Looking at this problem, the researchers conducted a randomized study to compare [...]

By Malecare|2013-02-17T10:43:04-05:00February 17th, 2013|adjuvant therapy, Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Drugs & Treatments, Hormone Therapy, Radiotherapy, Uncategorized|0 Comments

Two More Provenge Related Abstracts from the 2013 ASCO GU Symposium

More on Sipuleucel-T (Provenge) from the 2013 The last two abstracts that I want to speak about that were presented at the conference that pertained to Provenge speak to its efficacy. The first looks at changes in circulating tumor cells (CTC) and the second to the onset of the use of opioid painkillers. Abstract #40 [...]

By Malecare|2017-10-19T10:50:08-04:00February 15th, 2013|Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Drugs & Treatments, inflammation, Pain, Provenge, Research, Uncategorized, Understanding APC|0 Comments

Great News for the Advanced Prostate Cancer Community – The FDA Grants a Priority Review for Radium-223 Dichloride (Alpharadin)

Some more good news for the advanced prostate cancer community was announced today. Bayer HealthCare announced that the U.S. Food and Drug Administration (FDA) has granted priority review to their New Drug Application (NDA) filed in December 2012 for the investigational oncology compound radium-223 dichloride (radium-223). The application is under review for the treatment of [...]

By Malecare|2020-02-04T08:22:15-05:00February 13th, 2013|Advanced Prostate Cancer, Alpharadin (radium-223), Clinical Trials, Clinical Trials, FDA, General Information, Uncategorized|0 Comments

Chemotherapy Every Two Weeks Might Be Superior to the Standard Every Three Week Schedule Currently Used

Chemotherapy with Docetaxel is usually given on a once every three (3) week schedule of 75 mg/m2 administered intravenously + prednisolone (10 mg/day p.o.) for men with advanced prostate cancer. In the cases when the side effects are too difficult for a man to tolerate, the dose is often reduced to 50 mg/m2 administered intravenously [...]

By Malecare|2020-02-04T11:38:07-05:00January 18th, 2013|Advanced Prostate Cancer, Chemo Therapy, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Drugs & Treatments, Uncategorized, Understanding APC|1 Comment

Should I Start Chemotherapy While My Advanced Prostate Cancer Is Still Hormone Responsive?

I remember when I was first diagnosed with a prostate cancer recurrence, when I was told that I had advanced prostate cancer. More than any other times that I have been told I have cancer (I have melanoma, thyroid cancer, renal cancer and advanced prostate cancer) I felt the world stopped and my life was [...]

By Malecare|2013-01-16T10:17:23-05:00January 16th, 2013|Advanced Prostate Cancer, Chemo Therapy, Clinical Trials, Clinical Trials, Combination Therapy, Drugs & Treatments, Personal Experiences, Uncategorized, Understanding APC|0 Comments